American Journal of Clinical Dermatology

, Volume 16, Issue 3, pp 205–212 | Cite as

Exogenous Ochronosis: A Comprehensive Review of the Diagnosis, Epidemiology, Causes, and Treatments

  • Brian J. Simmons
  • Robert D. Griffith
  • Fleta N. Bray
  • Leyre A. Falto-Aizpurua
  • Keyvan Nouri
Review Article


Exogenous ochronosis (EO) can be an unintended psychologically troubling condition for patients who are already being treated for longer-term hyperpigmentation disorders such as melasma. Early diagnosis is key in order that the offending agent can be stopped to prevent further disfiguring discoloration. EO can be diagnosed in the right clinical setting with the aid of dermatoscopy, which can assist in early diagnosis and may negate the need for a biopsy. Laser modalities using Q-switched lasers of longer wavelengths and combination laser dermabrasion treatments have shown the most significant results with minimal adverse events. However, further large-scale studies are needed to determine optimal treatment modalities. Although considered uncommon, the incidence of EO will likely continue to increase with the growth of immigrant populations and the use of skin-lightening agents above the FDA’s recommended over-the-counter concentrations, without the guidance of a dermatologist.


Hydroquinone Yttrium Aluminium Garnet Intense Pulse Light Homogentisic Acid Reflectance Confocal Microscopy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Brian J. Simmons, Robert D. Griffith, Fleta N. Bray, Leyre A. Falto-Aizpurua, and Keyvan Nouri have no conflicts of interest to declare. No funding was used in the design and conduct of the study, collection, management, analysis and interpretation of data, preparation, review or approval of the manuscript, or in the decision to submit the manuscript for publication.


  1. 1.
    Findlay GH. Ochronosis. Clin Dermatol. 1989;7(2):28–35.PubMedGoogle Scholar
  2. 2.
    Mistry JB, Bukhari M, Taylor AM. Alkaptonuria. Rare Dis. 2013;1:e27475.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Beddard AP, Plumtre CM. A further note on ochronosis associated with carboluria. Q S Med. 1912;5:505–7.Google Scholar
  4. 4.
    Charlin R, Barcaui CB, Kac BK, Soares DB, Rabello-Fonseca R, Azulay-Abulafia L. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. Int J Dermatol. 2008;47(1):19–23.PubMedGoogle Scholar
  5. 5.
    Penneys NS. Ochronosis like pigmentation from hydroquinone bleaching creams. Arch Dermatol. 1985;121(10):1239–40.PubMedGoogle Scholar
  6. 6.
    Findlay GH, Morrison JG, Simson IW. Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. Br J Dermatol. 1975;93(6):613–22.PubMedGoogle Scholar
  7. 7.
    Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2(4):213–7.PubMedGoogle Scholar
  8. 8.
    Dogliotti M, Leibowitz M. Granulomatous ochronosis: a cosmetic-induced skin disorder in Blacks. S Afr Med J. 1979;56(19):757–60.PubMedGoogle Scholar
  9. 9.
    Jacyk WK. Annular granulomatous lesions in exogenous ochronosis are manifestation of sarcoidosis. Am J Dermatopathol. 1995;17(1):18–22.PubMedGoogle Scholar
  10. 10.
    Khunger N, Kandhari R. Dermoscopic criteria for differentiating exogenous ochronosis from melasma. Indian J Dermatol Venereol Leprol. 2013;79(6):819–21.PubMedGoogle Scholar
  11. 11.
    Liu WC, Tey HL, Lee JS, Goh BK. Exogenous ochronosis in a Chinese patient: use of dermoscopy aids early diagnosis and selection of biopsy site. Singapore Med J. 2014;55(1):e1–3.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Gil I, Segura S, Martinez-Escala E, Lloreta J, Puig S, Velez M, et al. Dermoscopic and reflectance confocal microscopic features of exogenous ochronosis. Arch Dermatol. 2010;146(9):1021–5.PubMedGoogle Scholar
  13. 13.
    Cullison D, Abele DC, O’Quinn JL. Localized exogenous ochronosis. J Am Acad Dermatol. 1983;8(6):882–9.PubMedGoogle Scholar
  14. 14.
    Zawar V, Tan S-K. Exogenous ochronosis: a review for clinicians. Expert Rev Dermatol. 2012;7(2):171–80.Google Scholar
  15. 15.
    US FDA. Docket no. 78N-0065; comments PRT 4 and PRT 5. US FDA; 1998.Google Scholar
  16. 16.
    US Census Bureau. US Census Bureau projections show a slower growing, older, more diverse nation a half century from now. 12 Dec 2012. Available at:
  17. 17.
    Galindo GR, Mayer JA, Slymen D, Almaguer DD, Clapp E, Pichon LC, et al. Sun sensitivity in 5 US ethnoracial groups. Cutis. 2007;80(1):25–30.PubMedGoogle Scholar
  18. 18.
    Werlinger KD, Guevara IL, Gonzalez CM, Rincon ET, Caetano R, Haley RW, et al. Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex. Arch Dermatol. 2007;143(3):424–5.PubMedGoogle Scholar
  19. 19.
    Sivayathorn A. Melasma in orientals. Clin Drug Invest. 1995;10(Suppl 2):34.Google Scholar
  20. 20.
    Tan SK. Exogenous ochronosis in ethnic Chinese Asians: a clinicopathological study, diagnosis and treatment. J Eur Acad Dermatol Venereol. 2011;25(7):842–50.PubMedGoogle Scholar
  21. 21.
    Bruce S, Tschen JA, Chow D. Exogenous ochronosis resulting from quinine injections. J Am Acad Dermatol. 1986;15(2 Pt 2):357–61.PubMedGoogle Scholar
  22. 22.
    Ribas J, Schettini AP. Cavalcante Mde S. Exogenous ochronosis hydroquinone induced: a report of four cases. An Bras Dermatol. 2010;85(5):699–703.PubMedGoogle Scholar
  23. 23.
    Olumide YM, Akinkugbe AO, Altraide D, Mohammed T, Ahamefule N, Ayanlowo S, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol. 2008;47(4):344–53.PubMedGoogle Scholar
  24. 24.
    Andersen FA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, et al. Final amended safety assessment of hydroquinone as used in cosmetics. Int J Toxicol. 2010;29(6 Suppl):274S–87S.PubMedGoogle Scholar
  25. 25.
    Levitt J. The safety of hydroquinone: a dermatologist’s response to the 2006 Federal Register. J Am Acad Dermatol. 2007;57(5):854–72.PubMedGoogle Scholar
  26. 26.
    Jow T, Hantash BM. Hydroquinone-induced depigmentation: case report and review of the literature. Dermatitis. 2014;25(1):e1–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Diven DG, Smith EB, Pupo RA, Lee M. Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser. J Dermatol Surg Oncol. 1990;16(11):1018–22.PubMedGoogle Scholar
  28. 28.
    Singh A, Ramesh V. Exogenous ochronosis. Indian J Med Res. 2014;139:327.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Schulz EJ, Summers B, Summers RS. Inappropriate treatment of cosmetic ochronosis with hydroquinone. S Afr Med J. 1988;73(1):59–60.PubMedGoogle Scholar
  30. 30.
    Camarasa JG, Serra-Baldrich E. Exogenous ochronosis with allergic contact dermatitis from hydroquinone. Contact Dermatitis. 1994;31(1):57–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Howard KL, Furner BB. Exogenous ochronosis in a Mexican–American woman. Cutis. 1990;45(3):180–2.PubMedGoogle Scholar
  32. 32.
    Lawrence N, Bligard CA, Reed R, Perret WJ. Exogenous ochronosis in the United States. J Am Acad Dermatol. 1988;18(5 Pt 2):1207–11.PubMedGoogle Scholar
  33. 33.
    Martin RF, Sanchez JL, Gonzalez A, Lugo-Somolinos A, Ruiz H. Exogenous ochronosis. P R Health Sci J. 1992;11(1):23–6.PubMedGoogle Scholar
  34. 34.
    Lang PG Jr. Probable coexisting exogenous ochronosis and mercurial pigmentation managed by dermabrasion. J Am Acad Dermatol. 1988;19(5 Pt 2):942–6.PubMedGoogle Scholar
  35. 35.
    Hoshaw RA, Zimmerman KG, Menter A. Ochronosis like pigmentation from hydroquinone bleaching creams in American blacks. Arch Dermatol. 1985;121(1):105–8.PubMedGoogle Scholar
  36. 36.
    Fisher AA. Tetracycline treatment for sarcoid-like ochronosis due to hydroquinone. Cutis. 1988;42(1):19–20.PubMedGoogle Scholar
  37. 37.
    Moche MJ, Glassman SJ, Modi D, Grayson W. Cutaneous annular sarcoidosis developing on a background of exogenous ochronosis: a report of two cases and review of the literature. Clin Exp Dermatol. 2010;35(4):399–402.PubMedGoogle Scholar
  38. 38.
    Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg. 2004;30(4 Pt 1):555–8.PubMedGoogle Scholar
  39. 39.
    Chaptini C, Huilgol SC. Erbium-doped yttrium aluminium garnet ablative laser treatment for endogenous ochronosis. Australas J Dermatol. doi: 10.1111/ajd.12199. Epub 10 Oct 2014.
  40. 40.
    Kramer KE, Lopez A, Stefanato CM, Phillips TJ. Exogenous ochronosis. J Am Acad Dermatol. 2000;42(5 Pt 2):869–71.PubMedGoogle Scholar
  41. 41.
    Lee MD, Weiss E. Treatment of exogenous ochronosis with advanced fluorescence technology. Dermatol Surg. 2014;40(9):1046–8.PubMedGoogle Scholar
  42. 42.
    Tan SK. Exogenous ochronosis: successful outcome after treatment with Q-switched Nd:YAG laser. J Cosmet Laser Ther. 2013;15(5):274–8.PubMedGoogle Scholar
  43. 43.
    Romero SA, Pereira PM, Mariano AV, Francesconi F, Francesconi VA. Use of dermoscopy for diagnosis of exogenous ochronosis. An Bras Dermatol. 2011;86(4 Suppl 1):S31–4.PubMedGoogle Scholar
  44. 44.
    Kanechorn-Na-Ayuthaya P, Niumphradit N, Aunhachoke K, Nakakes A, Sittiwangkul R, Srisuttiyakorn C. Effect of combination of 1064 nm Q-switched Nd:YAG and fractional carbon dioxide lasers for treating exogenous ochronosis. J Cosmet Laser Ther. 2013;15(1):42–5.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Brian J. Simmons
    • 1
  • Robert D. Griffith
    • 1
  • Fleta N. Bray
    • 1
  • Leyre A. Falto-Aizpurua
    • 1
  • Keyvan Nouri
    • 1
  1. 1.Department of Dermatology and Cutaneous SurgeryUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations